Shares of Compass Therapeutics CMPX have skyrocketed 108.3% in a month after the company announced updates regarding its ...

Rodman & Renshaw maintained a Buy rating on Compass Pathways (NASDAQ:CMPS) but significantly reduced the 12-month price ...

Compass Therapeutics, Inc.’s CMPX share price has surged by 14.18%, which has investors questioning if this is right time to ...

Compass said it cut its IPO price range from $23 to $26 down to $18 ... and calculated that its market share grew fourfold to 4% of US home sales by dollar volume between 2018 and 2020.

Morgan Stanley raised the firm’s price target on Compass (COMP ... investments widening its retail advantage to “take more share, more profitably,” while it calls Meta (META) a “GenAI ...

The average home price transacted by Compass in the third quarter of this ... has made progress on its goal of 30 percent market share in its top 30 cities, stating that the company is in the ...

with reference to the functional unblinding issue – is thought to have contributed to pressure on Compass' share price, which was down 16% at the time of writing. Functional unblinding refers to ...

Compass generated $2.1 billion of revenue in 2023 and is on track to post 5% organic revenue growth when it reports 2024 results next month. Its share price has swung widely but risen 10% over the ...

COMPASS Pathways: Institutional Pressure Amid $43M Market Cap Decline, What's Next For This Psychedelics Co? COMPASS Pathways faces $43M market cap loss, raising concerns among institutional ...

Compass Point raised the firm’s price target on Ares Capital (ARCC) to $24 from $23 and keeps a Buy rating on the shares. The firm is ...